USPTO serial 85773902
ACTAVIS
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- LEE, JANET H
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ACTAVIS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
PARSIPPANY, NJ
PARSIPPANY, NJ
PARSIPPANY, NJ
Hafnarfjordur, IS
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Gabrielle S. Roth
Gabrielle S. Roth Teva Pharmaceuticals USA Inc.425 Privet RoadHorsham, PA 19044UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals used in industry and science, namely, active chemical ingredients for use in the manufacture of pharmaceuticals, chemical additives for use in the manufacture of pharmaceuticals; chemical preparations for scientific purposes; chemical preparations for use in industry | ACTIVE | — |
| 003 | Soaps; Perfumery; Essential Oils; Cosmetics, namely, cosmetic preparations for skin care, cosmetic preparations for body care, cosmetic preparations for bath and shower, cosmetic creams, lotions, and ointments and gels for skin care, cosmetic skin fresheners and toners, cosmetic preparations for the hair and scalp, and hair lotions; Dentifrices, namely, anti-cavity dental rinses, mouth rinses and mouth washes, cosmetic preparations for the care of mouth and teeth | ACTIVE | — |
| 005 | Pharmaceutical preparations for the prevention and treatment of alimentary tract and metabolic diseases and disorders, dermatological diseases and disorders, genito-urinary and sexual diseases and disorders, musculo-skeletal system diseases and disorders, nervous system diseases and disorders, respiratory system diseases and disorders, cardio-vascular diseases and disorders specifically excluding tissue plasminogen activators; pharmaceutical preparations for the prevention and treatment of sensory organ diseases and disorders, systemic hormonal pharmaceutical preparations and substances, pharmaceuticals, namely, anti-infectives, pharmaceutical preparations, namely, antineoplastic and immunomodulating agents, antiparasitic preparations and substances; contraceptives; hormone replacement therapy preparations; pharmaceutical preparations for the prevention of preterm birth or pregnancy; pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; pharmaceutical preparations for the treatment and prevention of osteoporosis; pharmaceutical preparations for the treatment and prevention of endometriosis; pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; iron chelating pharmaceutical preparations; fertility enhancing preparations, pharmaceutical preparations and substances for the treatment of premenstrual syndrome, post natal depression, fluctuating hormone levels, pharmaceutical preparations and substances for infertility disorders, pharmaceutical preparations and substances for in vitro fertilization (ivf); pharmaceutical preparations in the nature of medicated dental rinses, mouth rinses, mouthwashes, dental lozenges, dental tablets and medicated chewing gum; dental wax; pharmaceutical preparations in the nature of pregnancy test kits, ovulation test kits and in-vitro ovulation prediction test kits all for home use; pharmaceutical preparations in the nature of diagnostic test kits for home use for detecting urinary tract infections, for detecting menopause, for detecting vaginal pH balances and for detecting sexually-transmitted diseases; pharmaceutical preparations for skin care; all the foregoing specifically excluding tissue plasminogen activators | ACTIVE | — |
| 041 | Education services, namely, conducting conferences, seminars, webinars, video case studies, classes and workshops in the fields of healthcare, women's health, pharmaceuticals and medicine, pharmaceutical research and development | ACTIVE | — |
| 042 | Scientific and technological services, namely, consulting in the field of pharmaceuticals pertaining to biotechnology, product evaluation, diagnostics, testing and inspection; pharmaceutical research and development; industrial analysis and research services in the field of pharmaceuticals and chemical analysis | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ACTAVIS, INC.
- Other trademarks owned by ACTAVIS, INC.
- Other trademarks owned by ACTAVIS HOLDCO US, INC.
- Other trademarks owned by Actavis Group PTC ehf
- Other trademarks in Class 001
- Other trademarks in Class 003
- Other trademarks in Class 005
- Other trademarks in Class 041
- Other trademarks in Class 042
- Similar marks named ACTAVIS
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 12, 2018 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Feb 12, 2018 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jul 27, 2017 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 26, 2017 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jul 20, 2017 | NREV | NOTICE OF REVIVAL - E-MAILED | — |
| Jul 19, 2017 | TPEX | SOU EXTENSION RECEIVED WITH TEAS PETITION | — |
| Jul 19, 2017 | PETG | PETITION TO REVIVE-GRANTED | — |
| Jul 19, 2017 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Jul 19, 2017 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 7, 2017 | EXT4 | SOU EXTENSION 4 FILED | — |
| Feb 22, 2017 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jan 6, 2017 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 4, 2017 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jan 4, 2017 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jan 4, 2017 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 2, 2016 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 1, 2016 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jul 29, 2016 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jun 28, 2016 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jun 28, 2016 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 25, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 23, 2015 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Nov 23, 2015 | EXT1 | SOU EXTENSION 1 FILED | — |
| Nov 23, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 7, 2015 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Feb 10, 2015 | TMBN | TTAB RELEASE CASE TO TRADEMARKS | — |
| Feb 10, 2015 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Feb 10, 2015 | OP.D | OPPOSITION DISMISSED NO. 999999 | — |
| Jan 30, 2014 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Aug 16, 2013 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Aug 6, 2013 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 6, 2013 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 17, 2013 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 3, 2013 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jul 2, 2013 | ALIE | ASSIGNED TO LIE | — |
| Jul 1, 2013 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 14, 2013 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 13, 2013 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 13, 2013 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 13, 2013 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| May 30, 2013 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 30, 2013 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 20, 2013 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Feb 5, 2013 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Feb 5, 2013 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Feb 5, 2013 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Feb 4, 2013 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 4, 2013 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 4, 2013 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 3, 2012 | GEAN | NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Dec 3, 2012 | GEAP | EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Dec 3, 2012 | EPEN | COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY | — |
| Dec 3, 2012 | CPEA | EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED | — |
| Nov 28, 2012 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 15, 2012 | MDSC | NOTICE OF DESIGN SEARCH CODE MAILED | — |
| Nov 14, 2012 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 10, 2012 | NWAP | NEW APPLICATION ENTERED | — |